Comparative immunogenicity and cross-clade protective efficacy of mammalian cell-grown inactivated and live attenuated H5N1 reassortant vaccines in ferrets

Journal of Infectious Diseases

Volumn 204, Issue 10, 2011, Pages 1491-1499

  Gustin, Kortney M ^a   Maines, Taronna R ^a   Belser, Jessica A ^a   Van Hoeven, Neal ^a   Lu, Xuihua ^a   Dong, Libo ^a   Isakova Sivak, Irina ^a,b   Chen, Li Mei ^a   Voeten, J Theo M ^c   Heldens, Jacco G M ^c   Van Den Bosch, Han ^c   Cox, Nancy J ^a   Tumpey, Terrence M ^a   Klimov, Alexander I ^a   Rudenko, Larisa ^b   Donis, Ruben O ^a   Katz, Jacqueline M ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Russian Federation)

^c Department of Virological RandD Nobilon International BV ^*  (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOLOGICAL ADJUVANT; INACTIVATED INFLUENZA H5N1 REASSORTANT VACCINE; INACTIVATED VACCINE; INFLUENZA VACCINE; LIVE ATTENUATED INFLUENZA H5N1 REASSORTANT VACCINE; LIVE VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; BOOSTER VACCINATION; BRAIN TISSUE; CELL STRAIN; CLADISTICS; CONFERENCE PAPER; CONTROLLED STUDY; CROSS PROTECTION; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; EXPERIMENTAL INFECTION; FERRET; GENETIC REASSORTMENT; IMMUNOGENICITY; INFLUENZA A (H5N1); INFLUENZA VACCINATION; INFLUENZA VIRUS A H5N1; LETHARGY; MALE; NASAL TURBINATE; NASAL WASH; NEUROLOGIC DISEASE; NONHUMAN; NOSE; PRIORITY JOURNAL; SAMPLING; SINGLE DRUG DOSE; SPLEEN; SURVIVAL; VACCINATION; VIRUS CULTURE; VIRUS SHEDDING; VIRUS STRAIN; VIRUS TITRATION; WEIGHT REDUCTION;

ANIMALS; ANTIBODIES, VIRAL; CROSS PROTECTION; FERRETS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; MALE; VACCINES, ATTENUATED; VACCINES, INACTIVATED; VACCINES, SYNTHETIC; VIRUS CULTIVATION; VIRUS SHEDDING;

EID: 80054752055     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir596     Document Type: Conference Paper

References (47)

1. Cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO. http://www.who.int/csr/disease/avian-influenza/country/cases- table-2010-11-19/en/index.html. Accessed 2 December 2010.
2. Abdel-Ghafar AN, Chotpitayasunondh T, Gao Z, et al. Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med 2008; 358:261-73.
3. World Health Organization. Antigenic and genetic characteristics of influenza A(H5N1) and influenza A(H9N2) viruses and candidate vaccine viruses developed for potential use in human vaccines. Geneva, Switzerland: World Health Organization (WHO), 2010.
4. Subbarao K, Luke C. H5N1 viruses and vaccines. PLoS Pathog 2007; 3:e40.
5. Karron RA, Talaat K, Luke C, et al. Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults. Vaccine 2009; 27:4953-60.
6. Rudenko L, Desheva J, Korovkin S, et al. Safety and immunogenicity of live attenuated influenza reassortant H5 vaccine (phase I-II clinical trials). Influenza Other Respi Viruses 2008; 2:203-9.
7. Belshe R, Lee MS, Walker RE, Stoddard J, Mendelman PM. Safety, immunogenicity and efficacy of intranasal, live attenuated influenza vaccine. Expert Rev Vaccines 2004; 3:643-54. (Pubitemid 39576751)
8. Lu X, Edwards LE, Desheva JA, et al. Cross-protective immunity in mice induced by live-attenuated or inactivated vaccines against highly pathogenic influenza A (H5N1) viruses. Vaccine 2006; 24:6588-93. (Pubitemid 46107146)
9. Minor PD, Engelhardt OG, Wood JM, et al. Current challenges in implementing cell-derived influenza vaccines: implications for production and regulation, July 2007, NIBSC, Potters Bar, UK. Vaccine 2009; 27:2907-13.
10. Doroshenko A, Halperin SA. Trivalent MDCK cell culture-derived influenza vaccine Optaflu (Novartis Vaccines). Expert Rev Vaccines 2009; 8:679-88.
11. Kendal AP, Maassab HF, Alexandrova GI, Ghendon YZ. Development of cold-adapted recombinant live, attenuated influenza A vaccines in the U.S.A. and U.S.S.R. Antiviral Res 1982; 1:339-65. (Pubitemid 12111394)
12. Isakova-Sivak I, Chen L, Matsuoka Y, et al. Genetic bases of the temperature-sensitive phenotype of a master donor virus used in live attenuated influenza vaccines: A/Leningrad/134/17/57 (H2N2). Virology 2011; 412:297-305.
13. Subbarao K, Chen H, Swayne D, et al. Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics. Virology 2003; 305:192-200. (Pubitemid 36062823)
14. WHO Global Influenza Program Surveillance Network. Evolution of H5N1 avian influenza viruses in Asia. Emerg Infect Dis 2005; 11:1515-21.
15. Logrippo GA. Investigations of the use of beta-propiolactone in virus inactivation. Ann N Y Acad Sci 1960; 83:578-94.
16. Influenza vaccine (whole virion, inactivated, prepared in cell cultures). European Pharmacopeia, Supplement 67, Monograph 2308. Strasbourg, France: EDQM-Council of Europe, 2009.
17. Palmer DF, Center for Disease Control, Bureau of Laboratories. Advanced laboratory techniques for influenza diagnosis. Repr. May 1979. Atlanta, GA: U. S. Dept. of Health, Education, and Welfare, Public Health Service, Center for Disease Control, Bureau of Laboratories, 1979. Immunology series no 6.
18. Maines TR, Lu XH, Erb SM, et al. Avian influenza (H5N1) viruses isolated from humans in Asia in 2004 exhibit increased virulence in mammals. J Virol 2005; 79:11788-00.
19. Reed LJ, Muench HA. A simple method of estimating fifty per cent endpoints. Am J Hyg 1938; 27:493-7.
20. Chosewood LC, Wilson DE. Centers for Disease Control and Prevention (U.S.), National Institutes of Health (U.S.). Biosafety in microbiological and biomedical laboratories. 5th ed. Washington, DC: U.S. Dept. of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, 2009. (For sale by the Supt. of Docs., U.S. G.P.O., 2009 HHS publication).
21. Katz JM, Lu X, Young SA, Galphin JC. Adjuvant activity of the heatlabile enterotoxin from enterotoxigenic Escherichia coli for oral administration of inactivated influenza virus vaccine. J Infect Dis 1997; 175:352-63. (Pubitemid 27052241)
22. Stevens J, Blixt O, Tumpey TM, Taubenberger JK, Paulson JC, Wilson IA. Structure and receptor specificity of the hemagglutinin from an H5N1 influenza virus. Science 2006; 312:404-10.
23. Kendal AP, Pereira MS, Skehel JJ. Concepts and procedures for laboratory-based influenza surveillance. Atlanta, GA: Centers for Disease Control, 1982.
24. Rowe T, Abernathy RA, Hu-Primmer J, et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 1999; 37:937-43. (Pubitemid 29140593)
25. Zitzow LA, Rowe T,Morken T, ShiehWJ, Zaki S, Katz JM. Pathogenesis of avian influenza A (H5N1) viruses in ferrets. J Virol 2002; 76:4420-9. (Pubitemid 34309579)
26. Reuman PD, Keely S, Schiff GM. Assessment of signs of influenza illness in the ferret model. J Virol Methods 1989; 24:27-34. (Pubitemid 19134878)
27. Belshe RB, Walker R, Stoddard JJ, Kemble G, Maassab HF, Mendelman PM. Influenza vaccine-live. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines. 5th ed: Elsevier, 2008:291-310.
28. Govorkova EA, Rehg JE, Krauss S, et al. Lethality to ferrets of H5N1 influenza viruses isolated from humans and poultry in 2004. J Virol 2005; 79:2191-8. (Pubitemid 40204576)
29. Govorkova EA, Webby RJ, Humberd J, Seiler JP, Webster RG. Immunization with reverse-genetics-produced H5N1 influenza vaccine protects ferrets against homologous and heterologous challenge. J Infect Dis 2006; 194:159-67. (Pubitemid 44087186)
30. Forrest HL, Khalenkov AM, Govorkova EA, Kim JK, Del Giudice G, Webster RG. Single-and multiple-clade influenza A H5N1 vaccines induce cross protection in ferrets. Vaccine 2009; 27:4187-95.
31. Baras B, Stittelaar KJ, Simon JH, et al. Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine. PLoS One 2008; 3:e1401.
32. Ellebedy AH, Ducatez MF, Duan S, et al. Impact of prior seasonal influenza vaccination and infection on pandemic A(H1N1) influenza virus replication in ferrets. Vaccine 2010; 29:3335-9.
33. Sambhara S, Poland GA. H5N1 Avian influenza: preventive and therapeutic strategies against a pandemic. Annu Rev Med 2010; 61:187-98.
34. Gupta RK. Aluminum compounds as vaccine adjuvants. Adv Drug Deliv Rev 1998; 32:155-72. (Pubitemid 28267407)
35. Hayden FG, Howard WA, Palkonyay L, Keiny MP. Report of the 5th meeting on the evaluation of pandemic influenza prototype vaccines in clinical trials: World Health Organization, Geneva, Switzerland, 12-13 February 2009. Vaccine 2009; 27:4079-89.
36. Zverev V. Safety and immunogenicity H5N2 LAV in volunteers. Pandemic Influenza Vaccine Clinical Trial Abstract Minimum Information, 2008.
37. Skehel JJ, Wiley DC. Receptor binding and membrane fusion in virus entry: The influenza hemagglutinin. Annu Rev Biochem 2000; 69:531-69.
38. Subbarao K, Joseph T. Scientific barriers to developing vaccines against avian influenza viruses. Nat Rev Immunol 2007; 7:267-78. (Pubitemid 46480953)
39. Balish AL, Davis CT, Saad MD, et al. Antigenic and genetic diversity of highly pathogenic avian influenza A (H5N1) viruses isolated in Egypt. Avian Dis 2010; 54:329-34.
40. Stevens J, Corper AL, Basler CF, Taubenberger JK, Palese P, Wilson IA. Structure of the uncleaved human H1 hemagglutinin from the extinct 1918 influenza virus. Science 2004; 303:1866-70. (Pubitemid 38374878)
41. Renegar KB, Small PA Jr, Boykins LG, Wright PF. Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract. J Immunol 2004; 173:1978-86. (Pubitemid 38971634)
42. Tamura S, Funato H, Hirabayashi Y, et al. Cross-protection against influenza A virus infection by passively transferred respiratory tract IgA antibodies to different hemagglutinin molecules. Eur J Immunol 1991; 21:1337-44.
43. Wright PF, Murphy BR, Kervina M, Lawrence EM, Phelan MA, Karzon DT. Secretory immunological response after intranasal inactivated influenza A virus vaccinations: evidence for immunoglobulin A memory. Infect Immun 1983; 40:1092-5. (Pubitemid 13103161)
44. Cox RJ, Brokstad KA, Ogra P. Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand J Immunol 2004; 59:1-15. (Pubitemid 38186834)
45. Lamm ME. Interaction of antigens and antibodies at mucosal surfaces. Annu Rev Microbiol 1997; 51:311-40. (Pubitemid 27433052)
46. Mazanec MB, Kaetzel CS, Lamm ME, Fletcher D, Nedrud JG. Intracellular neutralization of virus by immunoglobulin A antibodies. Proc Natl Acad Sci U S A 1992; 89:6901-5.
47. Girard MP, Katz J, Pervikov Y, Palkonyay L, Kieny MP. Report of the 6th meeting on the evaluation of pandemic influenza vaccines in clinical trials World Health Organization, Geneva, Switzerland, 17-18 February 2010. Vaccine 2010; 28:6811-20.